Role of miR-647 in human gastric cancer suppression

WENLONG CAO1*, WEIYUAN WEI1*, ZEXU ZHAN1, DONGYI XIE1, YUBO XIE2 and QIANG XIAO1

Departments of 1Surgery and 2Anaesthesiology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China

Received July 6, 2016; Accepted January 3, 2017

DOI: 10.3892/or.2017.5383

Abstract. MicroRNAs (miRNAs) regulate various oncogenes concomitantly, resulting in tumor suppression. They regulate proliferation and migration pathways in tumor development, suggesting a potential therapeutic role. In the present study, we found that miR-647 was markedly downregulated in gastric cancer (GC), and was significantly correlated with reduced tumor size and metastasis. In addition, miR-647 was also reduced in GC cell lines. Furthermore, overexpression of miR-647 in the GC cell lines inhibited cell proliferation, promoted cell cycle arrest at the G0/G1 phase and induced cell apoptosis. miR-647 also significantly inhibited tumor growth in vivo. Notably, we found that miR-647 overexpression suppressed the migration and invasion of the cancer cells, particularly liver metastasis in nude mice. miR-647 also reduced the expression levels of genes associated with proliferation and metastasis in tumors, including ANK2, FAK, MMP2, MMP12, CD44 and SNAIL1. Overall, our findings demonstrated that miR-647 exerts powerful antitumorigenic effects in vitro and in vivo, and may represent a promising therapeutic agent against GC.

Introduction

Globally, gastric cancer (GC) is one of the most common malignancies of the digestive tract with a 5-year patient survival rate of less than 25%, and represents the second leading cause of cancer-related deaths worldwide (1,2). Tumor growth and metastasis of GC are major causes of increased mortality. Unfortunately, due to the absence of biomarkers for early detection, most patients are often diagnosed in advanced stages of metastasis (3). Despite identification of the molecular mechanisms, the pathophysiology of GC remains largely obscure. Therefore, investigation of the regulatory mechanisms underlying the suppression of proliferation and metastasis of GC cells holds the key to effective diagnosis and treatment of GC.

MicroRNAs (miRNAs) regulate multiple genes and target pathways in several human diseases, including cancer, and therefore, represent potential therapeutic targets (4-6). miRNAs are endogenous small non-coding RNAs consisting of 19-24 nucleotides, each. They regulate gene expression by targeting the 3’-untranslated region of cancer-related mRNAs and function as a ‘fine-tuner’ in the most important biological processes, including proliferation, apoptosis, invasion and metastasis (7-9). These miRNAs have been shown to modulate pathways involved in GC cell proliferation and metastasis (10,11). Nevertheless, further investigation into the molecular mechanisms of miRNAs in GC is essential for early diagnosis or effective therapeutic intervention. Noteworthy, Rawlings-Goss et al found that miR-647 is associated with the most extensive cancers and may serve as a biomarker for GC (12). A recent study also reported that overexpression of miR-647 was associated with a better prognosis of Taxol-resistant ovarian cancer (13). However, the underlying role of miR-647 in GC remains indeterminate.

In the present study, miR-647 was found to play a tumor-suppressor role since inhibition of miR-647 expression in GC was strongly associated with tumor size and metastasis. Overexpression of miR-647 in GC cell lines in vitro and in vivo, inhibited proliferation and metastasis of GC via transcriptional regulation of genes including ANK2, FAK, MMP2, MMP12, CD44 and SNAIL1.

Materials and methods

Cell lines and clinical samples. Human GC samples and their corresponding adjacent non-tumor gastric tissues (located ~5 cm away from the tumor) were collected during surgical resection at The First Affiliated Hospital of Guangxi Medical University (Nanning, China) from 2013 to 2015. All samples were immediately frozen on dry ice and preserved in liquid nitrogen. All the patients provided written informed consent. The present study was approved by the Ethics Committee of The First Affiliated Hospital of Guangxi Medical University.
Four human GC cell lines (HGC-27, AGS, SGC-7901 and MGC-803) as well as immortalized gastric epithelial GES-1 cells were obtained from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). Cells were cultured in RPMI-1640 medium (GE Healthcare Life Sciences, South Logan, UT, USA) supplemented with 50 mg/ml penicillin, 100 mg/ml streptomycin, and 10% fetal bovine serum (FBS) at 37.8°C and 5.0% CO₂.

RNA extraction and quantitative reverse transcription real-time polymerase chain reaction (qRT-PCR). RNAs were extracted from tissue samples and cells using TRIzol (Invitrogen Corporation, Carlsbad, CA, USA). The cDNA was synthesized from 1,000 ng RNA samples using PrimeScript™ transcriptase real-time polymerase chain reaction (qRT-PCR). All primer sequences are listed in Table I.

Cell invasion assay. The Transwell insert was coated with 75 µl (1 µg/ml) Matrigel (BD Biosciences, Mountain View, CA, USA) and 5.0×10⁴ cells in 200 µl serum-free media were transferred to the upper chamber (6.5 mm; Corning, New York, NY, USA). The lower compartment was filled with 700 µl medium containing 5% FBS as a chemoattractant. After culturing for 24 h, the cells in the lower chamber were stained with Giemsa and the migrating cells were counted under a microscope from 8 randomly selected fields (magnification, x200).

Transfection. The miR-647 mimic and the null vector LV-GFP were purchased from GeneChem (Shanghai, China). Cells were transfected with the lentiviral vector at 25 PFU/cell (SGC-7901) or 60 PFU/cell (MGC-803) [multiplicity of infection (MOI), 25 or 60] at a cell confluency of 35%. Six groups of cells were identified as follows. Cells in the 7901-Ctrl (or 803-Ctrl) represent SGC-7901 (or MGC-803) cells without any treatment. Cells in the 7901-NC (or 803-NC) group were SGC-7901 (or MGC-803) cells transfected with the negative control lentiviral vector LV-GFP, and cells in the 7901-647 (or 803-647) group were SGC-7901 (or MGC-803) cells transfected with the recombinant lentivirus vector miR-647 mimic. After 24 h of transfection, the cells were cultured under normal conditions. The cells were then harvested and used.

Cell proliferation assay. Cell proliferation was assessed using the Cell Counting Kit-8 (CCK-8; Dojindo, Kumamoto, Japan). Cells in each group were transferred into 96-well plates at a density of 1.5×10⁴/well and incubated at 37°C and 5% CO₂ for 24, 48, 72 or 96 h followed by the addition of 10 µl of CCK-8 reagent into each well and incubation at 37°C for 4 h. The absorbance was read at 450 nm using a microplate reader.

Cell cycle assay. Flow cytometry was performed to analyze the cell cycle in 1×10⁶ trypsinized cells, fixed with 70% ethanol and stored at 4°C for 12 h. The cells were incubated in a 100 µl solution containing 200 ng/ml RNase at 37°C for 30 min. Propidium iodide (PI) (400 µl) was added. The cells were incubated at ambient temperature for 30 min in the dark. The results were analyzed using flow cytometry (BD Biosciences).

Cell apoptosis assay. An apoptosis detection kit (BD Biosciences) was used to determine the cellular apoptosis by incubating 2×10⁶ cells with 100 ml 1X binding buffer containing 50 µl/ml Annexin V-PE and 50 µl/ml 7-amino-actinomycin D. After incubation at an ambient temperature in the dark for 30 min, an additional 400 µl 1X binding buffer was added. The results were analyzed by flow cytometry (BD Biosciences).

Transmission electron microscopy (TEM). The ultrastructure of the cells was observed using TEM. The cells were fixed with 2.5% glutaraldehyde at 4°C overnight and post-fixed in 1% osmium tetroxide for 30 min, dehydrated in a graded series of ethanol baths, and embedded in Epon. Ultrathin sections were stained with uranyl acetate and lead citrate, and observed under a JEM-2000EX transmission electron microscope (Jeol, Tokyo, Japan).

Wound-healing assay. Cell migration was measured by culturing the GC cells in 6-well plates, and a straight line

| Gene     | Primer sequences                        |
|----------|----------------------------------------|
| miR-647  | 5'-GUGGCUCGACUCACUUCCUCUC-3'           |
| miR-647  | 5'-CTCAACTGTGTTGCGTGGAGA-3'            |
| U6       | 5'-TTATGGGTCCTAGCCTGAC-3'              |
| U6       | 5'-CACTATGGGCTGCGTGGAGA-3'             |
| ANK2     | 5'-CAGCTACATTGTTGCGTCTCTA-3'           |
| ANK2     | 5'-CTACACTGTGCGTGGAGA-3'               |
| ZNF609   | 5'-TGCTTTGTACATCCAGGCAAGA-3'           |
| ZNF609   | 5'-AGGCAGCTCAACGCAAAACCTC-3'           |
| KNDC1    | 5'-CTCCTACGCGGCAATCCACA-3'             |
| KNDC1    | 5'-TGCCACTAGCGTGGCTCTTAA-3'            |
| TRIM4    | 5'-CAGTGTCGCCAGATACATTGTAGA-3'         |
| TRIM4    | 5'-CTCCATCTCAGCAAAATGTTCC-3'           |
| FAK      | 5'-CACACCGTGCCAGCATATATATCCA-3'        |
| FAK      | 5'-CCATAGCAGGGCCACATCTTTA-3'           |
| MMP2     | 5'-AGGGTCTTTTGTGGTTACTCTGTGGA-3'       |
| MMP2     | 5'-AGGGTCTTTTGTGGTTACTCTGTGGA-3'       |
| MMP12    | 5'-AGGGTCTTTTGTGGTTACTCTGTGGA-3'       |
| MMP12    | 5'-AACACTGTGCTTTTGCTCTTGAGA-3'         |
| CD44     | 5'-AGGGTCTTTTGTGGTTACTCTGTGGA-3'       |
| CD44     | 5'-CTGGCCAAATGTTGTCAGACAG-3'           |
| SNAIL1   | 5'-CAAGCCCCAACCTAGTGTCAGGAGA-3'        |
| SNAIL1   | 5'-GGGAGGTTAGTGAGGAGTAGA-3'            |
| GAPDH    | 5'-GCACCGTCAAGGCTGAGAAC-3'             |
| GAPDH    | 5'-GGTGGAACAGGCAGTGGGA-3'              |

F, forward; R, reverse.
scratch wound was created with a 200-µl sterile pipette tip once cells attained 100% confluency. The wound conditions were monitored at 0, 24 and 48 h microscopically and the relative motility was calculated using the following formula: Relative motility = (initial distance - a time point distance)/initial distance x 100%.

Animal studies. All animals were provided by the Guangxi Animal Center (Nanning, China), and the animal studies were approved by the Ethics Committee of The First Affiliated Hospital of Guangxi Medical University. In vivo tumor growth was conducted with 2x10^6 GC cells in each group re-suspended in 100 µl of phosphate-buffered saline (PBS; Beyotime Institute of Biotechnology, Shanghai, China) and the cells were subcutaneously inoculated in the armpit region, respectively, of 5- to 6-week-old BALB/c nude mice (8 mice/group). After 3 days, the tumors increased in size to ~5.0 mm in diameter. The tumor size was measured every 3 days using a Vernier caliper and calculated by the formula: Tumor volume = a x b^2/2 (a, length diameter; b, width diameter). The relative tumor volume (RTV) was estimated as follows: RTV = V_t/V_0 (V_0, initial tumor volume; V_t, current tumor volume at the time of measurement). Mice were euthanized 21 days after inoculation of the cells. The xenografts were excised and embedded in paraffin for hematoxylin and eosin staining.

To study metastasis in vivo, 8x10^4 cells of each group were re-suspended in 100 µl PBS and intravenously injected into the tail vein of 5- to 6-week-old BALB/c nude mice (10 mice/group). After 36 days, lungs and livers were excised and embedded in paraffin for further histopathological analysis. The number of mice with metastasis was counted.

Microarray analysis and miR-647 target prediction. The microarray data obtained in the present study from cells in the 803-NC and 803-647 groups were deposited in the UniGene database 219. RNA samples were analyzed by microarray expression profiling using the GeneChip Hybridization Wash and Stain kit (Affymetrix, Santa Clara, CA, USA) according to the manufacturer's instructions. All the raw data were normalized by quantile method and analyzed. Genes upregulated and downregulated >1.5-fold in the 803-647 group compared with those in the 803-NC were selected. The target genes of miR-647 were analyzed by TargetScan (http://www.targetscan.org), microRNA.org (http://www.microrna.org/microrna/home.do) and MiRanda (http://www.miranda.com/).

Western blotting. Cell protein lysates were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to polyvinylidene fluoride (PVDF) membranes. After blocking with 5% non-fat milk, the membranes were incubated with the primary antibody overnight at 4°C and washed with Tris-buffered saline and Tween-20 (TBST). The membranes were incubated with a dilution of infrared-labeled secondary antibody (1:10,000) for 1 h. After washing twice with TBST, the optical density was quantified using software provided with the Odyssey scanner (LI-COR Biosciences, Lincoln, NE, USA).

Statistical analysis. Data are presented as mean ± SE as analyzed by SPSS 13.0 (SPSS, Inc., Chicago, IL, USA), and deemed to have statistical significance at P<0.05 using the Student's t-test, one-way analysis of variance (ANOVA) or χ² test.

Results

Downregulation of miR-647 in GC correlates with proliferation and metastasis. To determine the role of miR-647 in the pathogenesis of GC, we investigated the miR-647 levels in GC tissue specimens and the corresponding non-tumor samples of 70 GC patients and 4 GC cell lines using qRT-PCR. As shown in Fig. 1A, compared with the corresponding non-tumor samples, the miR-647 level in the GC tissue specimens was significantly decreased in 43 of 70 patients (P<0.05). The histogram also demonstrated an average 0.79±0.09-fold downregulation of miR-647 in the GC tissue specimens compared with that noted in the non-tumor samples (P<0.05; Fig. 1B). To address the clinical significance of the downregulation of miR-647 in GC, the relationship between miR-647 expression and clinical pathology was determined (Table II). The GC samples were assigned a cut-off point to distinguish tumors with low-level expression of miR-647 from those with high-level expression of miR-647. Correlation analysis showed that the low-level expression of miR-647 in GC was significantly correlated with the clinical characteristics of the gastric cancer patients (n=70).

| Characteristics | Total cases | miR-647 |
|-----------------|-------------|---------|
|                 |            | High (n) | Low (n) | P-value |
| Age, years      |            |          |         |         |
| <60             | 40         | 14       | 26      | 0.478   |
| ≥60             | 30         | 13       | 17      |         |
| Gender          |            |          |         | 0.698   |
| Male            | 50         | 20       | 30      |         |
| Female          | 20         | 7        | 13      |         |
| Tumor size (cm) |            |          |         | 0.012   |
| >3              | 57         | 18       | 39      |         |
| ≤3              | 13         | 9        | 4       |         |
| TNM staging     |            |          |         | 0.007   |
| I/II            | 30         | 17       | 13      |         |
| III/IV          | 40         | 10       | 30      |         |
| Node metastasis |            |          |         | 0.007   |
| None            | 23         | 14       | 9       |         |
| Metastasis      | 47         | 13       | 34      |         |
| Distant metastasis |        |          |         | 0.028   |
| None            | 49         | 23       | 26      |         |
| Metastasis      | 21         | 4        | 17      |         |
| Differentiation |            |          |         | 0.797   |
| Poor or undifferentiated | | | | |
| Moderate or well| 22         | 8        | 14      |         |
| Metastasis      | 47         | 13       | 34      |         |
| Distant metastasis |        |          |         | 0.028   |
| None            | 49         | 23       | 26      |         |
| Metastasis      | 21         | 4        | 17      |         |
| Distant metastasis |        |          |         | 0.797   |
| Poor or undifferentiated | | | | |
| Moderate or well| 22         | 8        | 14      |         |

TNM, tumor-node-metastasis. *P<0.05.
associated with tumor size, tumor-node-metastasis (TNM) staging and metastasis including lymph node metastasis and distant metastasis that characterize more aggressive tumor phenotypes (P<0.05; Table II).

Since miR-647 was downregulated in GC and associated with tumor growth and metastasis, we speculated that it may play a similar role in GC cells. The expression of miR-647 was also investigated. Consistent with the results in GC patients, the expression of miR-647 in the HGC-27, AGS, SGC-7901 and MGC-803 cell lines was significantly downregulated with a fold-change of 0.58±0.03, 0.57±0.03, 0.32±0.03 and 0.10±0.00, respectively, compared with that noted in the GES-1 cells (P<0.05; Fig. 1C). We next investigated the invasive ability of the GC cell lines using the Transwell assay. The data demonstrated that the GC cell lines MGC-803 and SGC-7901 displayed a stronger invasive ability with lower levels of miR-647 compared with HGC-27 and AGS cell lines (P<0.05; Fig. 1D). Overall, these results suggest that miR-647 expression is frequently downregulated in GC, and is correlated with proliferation and metastasis, suggesting that miR-647 acts as a tumor-suppressor in GC development.

**miR-647 suppresses GC cell growth.** To explore the potential growth-suppressive role of miR-647 in GC, we first established GC cells stably overexpressing miR-647. The miR-647 mimic and LV-GFP were transfected into SGC-7901 or MGC-803 cells that displayed a stronger invasive ability, respectively. The expression of miR-647 in the stably transfected cells was confirmed by qRT-PCR (P<0.05; Fig. 2A). Cell proliferation assays revealed that miR-647 overexpression significantly reduced the growth rates of the SGC-7901 and MGC-803 cells (P<0.05; Fig. 2B). As shown in Fig. 2C, cell cycle analysis also supported the results, as overexpression of miR-647 was related to G0/G1 phase arrest. Cell counts in the G0/G1 phase

---

**Figure 1. Downregulation of miR-647 in gastric carcinoma (GC) is associated with proliferation and metastasis.**

(A) The expression levels of miR-647 in GC tissues compared with the expression in adjacent normal tissues in 70 patients. (B) Quantitative reverse transcription real-time polymerase chain reaction (qRT-PCR) of miR-647 expression in GC tissues of patients and adjacent non-tumor tissues. (C) qRT-PCR analysis of miR-647 expression in GC cell lines. (D) Transwell assay of GC cell invasion; *P<0.05. All values represent mean ± SE.
apparently increased while those in the S phase decreased (P<0.05). Furthermore, we found that miR-647 increased the basal rate of cells undergoing apoptosis (P<0.05, Fig. 2D). As shown in Fig. 2E, typical features of apoptosis such as formation of apoptotic bodies, chromatin fragmentation or concentration and mitochondrial disappearance or crest fracture were observed in the 7901-647 and 803-647 groups under TEM. Consistent with the results obtained in the in vitro growth assays, miR-647 significantly inhibited the xenograft tumor growth in nude mice (P<0.05, Fig. 2F and G). Collectively, these data clearly demonstrate that miR-647 plays a growth-suppressive function in GC.
miR-647 suppresses GC metastasis. We confirmed that the ectopic expression of miR-647 is closely associated with GC metastasis including lymph node and distant metastasis; that is to say, miR-647 mediates the processes of metastasis in the development of GC. To determine the role of miR-647 in metastasis, the effect of miR-647 overexpression on cell migration and invasion was investigated using wound-healing and Transwell assays with Matrigel. The results demonstrated that overexpression of miR-647 in the SGC7901 and MGC803 cells substantially impaired cell migration (P<0.05; Fig. 3A). Similarly, miR-647 significantly decreased GC cell invasion in the Matrigel-coated Transwell assay (P<0.05; Fig. 3B). To probe the effect of abnormal expression of miR-647 on tumor metastasis in vivo, controls and miR-647-overexpressing cells were injected into nude mice via the lateral tail vein. As

Table III. Cases of metastasis in lung and liver tissue in a model of metastasis in nude mice for each group (*P<0.05).

| Groups      | Total cases | Lung metastasis | Liver metastasis |
|-------------|-------------|-----------------|------------------|
|             | Cases       | Ratio (%)       | P-value | Cases       | Ratio (%) | P-value |
| 7901-Ctrl   | 10          | 4 40            | 0.451   | 7           | 70        | 0.035*  |
| 7901-NC     | 10          | 3 30            |         | 5           | 50        |         |
| 7901-647    | 10          | 1 10            |         | 1           | 10        |         |
| 803-Ctrl    | 10          | 4 40            | 0.293   | 6           | 60        | 0.061   |
| 803-NC      | 10          | 4 40            |         | 7           | 70        |         |
| 803-647     | 10          | 1 10            |         | 2           | 20        |         |

Figure 2. Continued. (F) Xenografts of each group and tumor segments stained with hematoxylin and eosin (magnification, x200). (G) Relative tumor volume (RTV) of each group; *P<0.05 for the 7901-647 (803-647) group vs. the 7901-NC (803-NC) and 7901-Ctrl (803-Ctrl) groups. All values represent mean ± SE.
shown in Fig. 3C and Table III, the result was confirmed by histological staining and statistical analysis, demonstrating that miR-647 overexpression strongly inhibited the ability of GC metastases in the liver. These results clearly indicate that miR-647 suppresses GC migration and invasion.

miR-647 modulates proliferation and metastasis by reducing the expression of ANK2, FAK, MMP2, MMP12, CD44 and SNAIL1. To investigate the molecular mechanisms of miR-647-mediated tumor suppression, potential direct targets for miR-647 were screened by microarray data
CAO et al: miR-647 SUPPRESSES GASTRIC CANCER PROLIFERATION AND METASTASIS

Figure 4. ANK2 is a potential target of miR-647. miR-647 mediates proliferation and metastasis by reducing the expression of ANK2, FAK, MMP2, MMP12, CD44 and SNAIL1. (A) Potential target genes of miR-647 were screened by microarray gene expression profiling combined with bioinformatic target prediction. (B) Quantitative reverse transcription real-time polymerase chain reaction (qRT-PCR) analysis of potential target genes. (C) Western blotting of ANK2 protein. (D) Results of TargetScan and microRNA predicted the target gene of miR-647. *P<0.05 for 7901-647 (803-647) group vs. the 7901-NC (803-NC) and 7901-Ctrl (803-Ctrl) groups; #P>0.05 for 7901-647 group vs. the 7901-NC and 7901-Ctrl groups. All values are expressed as mean ± SE.

analysis combined with bioinformatic target prediction. The functional downstream genes for miR-647 were selected via gene expression profiling of 803-647 and 803-NC cells. Of the 31,741 genes analyzed by UniGene Whole Genome DNA array analysis, 113 and 110 were upregulated and downregulated, respectively, which had an expression change >1.5-fold in GC cells of the 803-647 group compared with the 803-NC group. Following suppression of most targets by miRNAs, the downregulation of 110 genes in the 803-647 group was analyzed for potential miR-647 direct targets predicted by at least two of the 3 computational target prediction algorithms (miRanda, TargetScan and microRNA). Four potential miR-647 targets, ANK2, ZNF609, KNDC1 and TRIM4 were identified (Fig. 4A). To examine whether or not the 4 potential
targets were regulated by miR-647 in GC cell lines, the miR-647 overexpression of SGC7901 and MGC803 cells was analyzed for transcriptional expression of ANK2, ZNF609, KNDC1 and TRIM4 by qRT-PCR. As shown in Fig. 4B, among the 4 potential targets, ANK2 and KNDC1 mRNA expression was suppressed by miR-647 in both cells. Since only ANK2 plays an oncogenic function in tumorigenesis, it was selected for further evaluation as the miR-647 potential target. Furthermore, suppression of ANK2 expression by miR-647 overexpression was confirmed in the SGC7901 and MGC803 cells (P<0.05; Fig. 4C). As shown in Fig. 4D, ANK2 was a potential target of miR-647 as predicted by TargetScan and miRNA.

To investigate the mechanism by which miR-647 suppresses GC proliferation and metastasis, we utilized qRT-PCR and western blotting to determine the expression of genes that regulate proliferation and metastasis. Our data demonstrated that the expression of FAK, MMP2, MMP12, CD44 and SNAIL1 was downregulated after miR-647 overexpression in both SGC7901 and MGC803 cell lines (P<0.05, Fig. 4E and F).

Discussion

According to the 2012 statistics of the International Agency for Research on Cancer (IARC), gastric cancer is the fifth most common malignancy, and the third leading cause of cancer-related deaths worldwide (14). Recently, tumor invasion, metastatic dissemination, disease relapse, and drug resistance have been identified as classical hallmarks of cancer malignancy, and represent major factors contributing to poor clinical outcomes in cancer patients (15,16). Unfortunately, due to lack of effective diagnostic methods for early stage disease and tumorigenesis in GC, patients are often diagnosed with metastatic disease. Therefore, the discovery of novel molecular biomarkers and targets for diagnosis and treatment of GC is imperative.

Emerging evidence indicates that miRNAs modulate the development of GC. They are closely involved in the regulation of various biological and pathological processes, including tumor growth, cell invasion and tumor metastasis (16,17). Notably, Yang et al (18) reported that miR-647 expression is significantly altered during lymphatic metastasis.
of GC. A recent study also showed that miR-647 is associated with malignant cancer phenotypes and is often used as a biomarker for GC (12). However, miR-647 is a newly identified molecule, with limited data supporting its role in GC. The evidence suggests that miR-647 may function as a tumor suppressor or tumorigenic miRNA. In the present study, we found a significant decrease in the level of miR-647 expression in GC tumors compared with that in the corresponding non-tumor tissues. We further analyzed the correlation of miR-647 expression with clinicopathological characteristics. A robust association between low miR-647 expression and tumor size, lymph node and distant metastases was confirmed in 70 patients with GC. Furthermore, consistent with the results in GC patients, we showed that the expression of miR-647 in SGC-7901, MGC-803, HGC-27 and AGS cells was significantly downregulated compared with that in the GE-1 cells. The SGC-7901 and MGC-803 cells, with lower levels of miR-647, displayed higher invasive ability compared with the HGC-27 and AGS cell lines. These findings suggest that miR-647 plays a tumor-suppressor role in GC and acts as a metastatic biomarker in GC.

To investigate the effect of miR-647 on the proliferation and metastasis of GC cell lines, we re-expressed miR-647 in GC cell lines SGC7901 and MGC803, both of which express a low basal level of miR-647. Re-expression of miR-647 effectively slowed tumor cell growth, inhibited cell cycle entry into the S phase and increased apoptosis as well as suppressed GC xenograft tumor growth in nude mice. In addition, re-expression of miR-647 decreased tumor cell migration and invasion. Consistently, an experimental animal model of metastasis also confirmed that miR-647 significantly reduced the colonization of metastatic tumors in liver. These data point toward an important role of miR-647, similar to a tumor suppressor, in GC cell growth and metastasis.

To further elucidate the mechanism underlying the role of miR-647, we used three open access programs (miRanda, TargetScan and microRNA) and Microarray Data Analysis to predict targets of miR-647. Among the 4 potential targets (ANK2, ZNF609, KNDC1 and TRIM4), the mRNA expression of KNDC1 and ANK2 was suppressed by miR-647 overexpression in the SGC7901 and MGC803 cells. As ANK2 was previously reported to play an oncogenic role, we focused on the oncogene ANK2 as the potential target. Furthermore, we confirmed that miR-647 overexpression suppressed ANK2 protein expression. Cytoskeletal proteins are positively associated with cell growth and metastasis (19,20). As a member of the cytoskeletal protein family, ANK2 encodes one of the 3 ankyrins: ankyrin-R (ANK1), ankyrin-B (ANK2) and ankyrin-G (ANK3), mediating various integral membrane proteins (21,22). Overexpression of ankyrins has been observed in various cancer cells, including prostate, breast and ovarian cancers (23-25). They play a crucial role in cell growth, membrane transportation, metastasis and migration of cancer cells (22,23). Furthermore, consistent with the present study, a recent study showed that ANK2 was overexpressed in pancreatic tumors and downregulation of ANK2 attenuated the growth and invasion of pancreatic cancers (26). However, there is no sufficient evidence to support the role of ANK2 in GC. Our findings suggest that miR-647 inhibits proliferation and metastasis in GC by downregulating ANK2. To the best of our knowledge, the present study provides initial evidence supporting the role of miR-647 in the downregulation of ANK2 in GC.

We also demonstrated that FAK, MMP2, MMP12, CD44 and SNAIL1 are downstream effectors of miR-647-ANK2 based on interference studies demonstrating that FAK, MMP2, MMP12, CD44 and SNAIL1 expressions were decreased by miR-647-ANK2 expression. The ANK2/FAK/MMP2/MMP12 and ANK2/CD44/SNAIL1 signaling pathways represent a rare integrated network mediating the proliferation and metastasis of GC. Our results were consistent with previous data indicating that ANK2 may affect signal transduction mediated by FAK activity. FAK plays a pivotal role in the secretion of matrix metalloproteinases (MMPs) (26,27). As a potential prognostic indicator, decreased focal adhesion kinase (FAK) expression mediates the inhibition of cell proliferation and limits the induction of metastasis in GC (28,29). Additionally, MMP2 and MMP12 belong to the group of MMPs, which are known for their key role in tumor metastasis and invasiveness (30,31). Recent studies have shown that inhibition of MMP2 and MMP12 suppresses the invasion of gastric and lung cancers (32,33).

Ankyrins (including ANK1, ANK2 and ANK3) link various transmembrane proteins to actin network, and bind to CD44 domains. CD44, an important cell membrane receptor, which consists of a conserved intracellular ankyrin-binding region, links the external environment to the cytoskeleton. It mediates a variety of cellular behaviors including mitogenesis, adhesion and migration and was found to interact with growth and metastasis in malignant cells (34-36). Inhibition of CD44 was found to decrease the expression of SNAIL1 and the potential for invasion in pancreatic cancer cells (37,38). Recent studies have shown that epithelial-to-mesenchymal transition (EMT) is associated with the acquisition of metastasis in GC cells (39). The transcription factor SNAIL1 represses epithelial factors such as E-cadherin, and its expression is sufficient for EMT (40). Consequently, inhibition of SNAIL1 expression prevents EMT resulting in suppression of cell proliferation and metastasis (41).

In conclusion, in the present study, miR-647 expression was found to decrease the expression of ANK2/FAK/MMP2/MMP12 and ANK2/CD44/SNAIL1 signaling pathways, directly or indirectly, resulting in inhibition of the proliferation and metastasis of GC cells in vitro and in vivo. For the first time, the present study demonstrated a relationship between miR-647 and ANK2, indicating the potential role of miR-647 in the regulation of GC development. Furthermore, it underscores the role of miR-647 as a potential biomarker in GC and further investigation should be carried out to confirm that targeting this gene may aid in the diagnosis and treatment of gastric carcinoma.

Acknowledgements

The present study was supported by grants from the National Natural Science Foundation of China (nos. 81660511, 30860273 and 81060201), the Natural Science Foundation of Guangxi (no. 2015GXNSFDA227001), the Key Health Science Foundation of Guangxi (no. 14124004-1-9), and the Innovation Project of Guangxi Graduate Education.
References

1. Hamashima C: Current issues and future perspectives of gastric cancer screening. World J Gastroenterol 20: 13767-13774, 2014.
2. Shmulevich I: Large-scale molecular characterization and analysis of gastric cancer. Chin J Cancer 33: 369-370, 2014.
3. Piazuelo MB and Correa P: Gastric cancer: Overview. Colomb Med 44: 192-201, 2013.
4. Ambros V: The functions of animal microRNAs. Nature 431: 350-355, 2004.
5. Alizadeh S, Azizi SG, Soleimani M, Farshi Y and Kashani Khabir Z: The role of microRNAs in myeloproliferative neoplasia. Int J Hematol Oncol Stem Cell Res 10: 172-185, 2016.
6. Zhao Y and Srivastava D: A developmental view of microRNA function. Trends Biochem Sci 32: 189-197, 2007.
7. Bushati N and Cohen SM: microRNA functions. Annu Rev Cell Dev Biol 23: 175-205, 2007.
8. Esquela-Kerscher A and Slack FJ: Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 6: 259-269, 2006.
9. Hata A and Lieberman J: Dysregulation of microRNA biogenesis and gene silencing in cancer. Sci Signal 8: re3, 2015.
10. Zheng H, Zhang F, Lin X, Huang C, Zhang Y, Li Y, Lin J, Chen W and Lin X: MicroRNA-1225p inhibits proliferation and metastasis of gastric carcinoma through repressing insulin receptor substrate-1 and activation of β-catenin signaling. Oncotarget 7: 4647-4663, 2016.
11. Wu QF, Zhu R, Li BS, Zhao YL, Zhang Y, Yu T, Gong L, Li S, Xiao B and Zou QM: MicroRNA-141 inhibits tumor growth and metastasis in gastric cancer by directly targeting transcriptional co-activator with PDZ-binding motif, TAZ. Cell Death Dis 6: e1623, 2015.
12. Rawlings-Goss RA, Campbell MC and Tishkoff SA: Global population-specific variation in miRNA associated with cancer risk and clinical biomarkers. BMC Med Genomics 7: 53, 2014.
13. Kim YW, Kim EY, Jeon D, Liu JL, Kim HS, Choi JW and Ahn WS: Differential microRNA expression signatures and cell type-specific association with Tazx resistance in ovarian cancer cells. Drug Des Devel Ther 8: 293-314, 2014.
14. Yuan DD, Zhu L, Ito T, Nakahara T, Matsuda S, Yamamoto T and Hamaguchi M: A role for FAK in the Concanavalin A-dependent secretion of matrix metalloproteinase-2 and -9. Oncogene 19: 5359-5364, 2000.
15. Nishida T, Egashira Y, Akutagawa H, Fujii M, Uchiyama K, Watanabe T: Matrix metalloproteinase-12 gene expression in human vascular smooth muscle cells. Genes Cells 8: 225-234, 2003.
16. Sein TT, Thant AA, Hiraia Y, Amin AR, Sohara Y, Liu Y, Matsuda S, Yamamoto T and Hamaguchi M: A role for FAK in the Concanavalin A-dependent secretion of matrix metalloproteinase-2 and -9. Oncogene 19: 5359-5364, 2000.
17. Chun Y, Lohr M and Jesnowski R: Inhibition of ankyrin-B expression reduces growth and invasion of human pancreatic ductal adenocarcinoma. Pancreatology 10: 586-596, 2010.
18. Ahn WS: Differential microRNA expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells. Drug Des Devel Ther 8: 293-314, 2014.
19. Zhu L, Ito T, Nakahara T, Matsuda S, Yamamoto T and Hamaguchi M: A role for FAK in the Concanavalin A-dependent secretion of matrix metalloproteinase-2 and -9. Oncogene 19: 5359-5364, 2000.
20. Chen Y, Lohr M and Jesnowski R: Inhibition of ankyrin-B expression reduces growth and invasion of human pancreatic ductal adenocarcinoma. Pancreatology 10: 586-596, 2010.
21. Pelgrum YM, Segers V, Hens N, De Wachter JP, Van den Hoogen V, Onken NC, et al: Upregulation of Snai1 and suppression of Snai2 in gastric cancer cells. Cytoskeleton 39: 209-222, 1998.
22. Shibayama Y and Hirose Y: Predictors of lymph node metastasis in gastric cancer. Ann Surg Oncol 16: 600-609, 2009.
23. Zhi D and Bourguignon LY: Interaction between CD44 and the repeat domain of ankyrin promotes hyaluronic acid-mediated ovarian cancer cell migration. J Cell Physiol 183: 182-195, 2000.
24. Bourguignon LY, Zhi H, Shao L and Chen YW: Ankyrin-Tiam1 interaction promotes Rac1 signaling and metastatic breast tumor cell invasion and migration. J Cell Biol 150: 177-191, 2000.
25. Zhi D and Bourguignon LY: The ankyrin-binding domain of CD44s is involved in regulating hyaluronic acid-mediated functions and prostate tumor cell transformation. Cell Motil Cytoskeleton 39: 209-222, 1998.
26. Kudo-Saito C, Shirako H, Takenuti T and Kawakami Y: Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells. Cancer Cell 15: 195-206, 2009.